News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fisher Biosciences Unit, Cellomics, Inc., And Evotec Technologies Sign License Agreement


1/30/2006 11:39:10 AM

PITTSBURGH & HAMBURG, Germany--(BUSINESS WIRE)--Jan. 30, 2006--Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH announced today that they have entered into a worldwide, non-exclusive patent license agreement. The agreement will provide Evotec Technologies with Cellomics' core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES